Chase TN - Search Results

1

Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease.

Chase TN, Engber TM, Mouradian MM. Chase TN, et al. Adv Neurol. 1996;69:497-501. Adv Neurol. 1996. PMID: 8615171 Review. No abstract available.

2

Striatal plasticity and extrapyramidal motor dysfunction.

Chase TN. Chase TN. Parkinsonism Relat Disord. 2004 Jul;10(5):305-13. doi: 10.1016/j.parkreldis.2004.02.012. Parkinsonism Relat Disord. 2004. PMID: 15196510 Review.

3

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.

Bara-Jimenez W, Dimitrova T, Sherzai A, Favit A, Mouradian MM, Chase TN. Bara-Jimenez W, et al. Among authors: chase tn. Mov Disord. 2004 Oct;19(10):1183-6. doi: 10.1002/mds.20124. Mov Disord. 2004. PMID: 15390018 Clinical Trial.

4

Glutamate release inhibition ineffective in levodopa-induced motor complications.

Bara-Jimenez W, Dimitrova TD, Sherzai A, Aksu M, Chase TN. Bara-Jimenez W, et al. Among authors: chase tn. Mov Disord. 2006 Sep;21(9):1380-3. doi: 10.1002/mds.20976. Mov Disord. 2006. PMID: 16758479 Clinical Trial.

5

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.

Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN. Bara-Jimenez W, et al. Among authors: chase tn. Mov Disord. 2005 Aug;20(8):932-6. doi: 10.1002/mds.20370. Mov Disord. 2005. PMID: 15791634 Clinical Trial.

6

Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.

Bibbiani F, Costantini LC, Patel R, Chase TN. Bibbiani F, et al. Among authors: chase tn. Exp Neurol. 2005 Mar;192(1):73-8. doi: 10.1016/j.expneurol.2004.11.013. Exp Neurol. 2005. PMID: 15698620

7

Mapping of rat brain using the Synuclein-1 monoclonal antibody reveals somatodendritic expression of alpha-synuclein in populations of neurons homologous to those vulnerable to Lewy body formation in human synucleopathies.

Andringa G, Du F, Chase TN, Bennett MC. Andringa G, et al. Among authors: chase tn. J Neuropathol Exp Neurol. 2003 Oct;62(10):1060-75. doi: 10.1093/jnen/62.10.1060. J Neuropathol Exp Neurol. 2003. PMID: 14575241

8

Striatal glutamatergic mechanisms and extrapyramidal movement disorders.

Chase TN, Bibbiani F, Oh JD. Chase TN, et al. Neurotox Res. 2003;5(1-2):139-46. doi: 10.1007/BF03033378. Neurotox Res. 2003. PMID: 12832228 Review.

9

Complications of a trophic xenotransplant approach in parkinsonian monkeys.

Blanchet PJ, Konitsiotis S, Mochizuki H, Pluta R, Emerich DF, Chase TN, Mouradian MM. Blanchet PJ, et al. Among authors: chase tn. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Jun;27(4):607-12. doi: 10.1016/s0278-5846(03)00048-4. Prog Neuropsychopharmacol Biol Psychiatry. 2003. PMID: 12787846

10

Renaissance of amantadine in the treatment of Parkinson's disease.

Blanchet PJ, Metman LV, Chase TN. Blanchet PJ, et al. Among authors: chase tn. Adv Neurol. 2003;91:251-7. Adv Neurol. 2003. PMID: 12442683 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results